TransCon CNP for Achondroplasia

Adebola Giwa, MD Associate Medical Director, Clinical Development /Ascendis Pharma
Carl Decker, PhD Clinical Scientist, Clinical Development /Ascendis Pharma

The latest information on the development of TransCon CNP for patients with achondroplasia (ACH). TransCon CNP is an investigational long-acting prodrug of CNP in development for the treatment of ACH in children.